Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

24.7K
Hepatitis C Virus (HCV) is a major human pathogen that causes liver disorders, including cirrhosis and cancer. An HCV infectious cell culture system is essential for understanding the molecular mechanism of HCV replication and developing new therapeutic approaches. Here we describe a protocol to investigate various stages of the HCV replication cycle.
24.7K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

7.9K
This manuscript describes a detailed protocol for Hepatitis B virus (HBV) infection in novel engineered 293T cells (293T-NE-3NRs, expressing human NTCP, HNF4α, RXRα and PPARα) and traditional hepatic cells (HepG2-NE, expressing human...
7.9K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

13.9K
Here we describe a newly developed hepatitis B virus (HBV) reporter system to monitor the early stages of the HBV life cycle. This simplified in vitro system will aid in the screening of anti-HBV agents using a high-throughput...
13.9K
Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery04:46

Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery

596
The video demonstrates locoregional delivery of oncolytic viruses through hepatic arterial injection as a therapeutic approach for hepatocellular carcinoma. These viruses selectively replicate in tumor cells, inducing cell lysis and releasing tumor cell-associated antigens. This process triggers immunogenic cell death, inducing an anti-tumor...
596
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

10.3K
Described here is an effective method on how to produce high viral titer stocks of hepatitis E virus (HEV) to efficiently infect hepatoma cells. With the presented method, both non-enveloped, as well as enveloped viral particles can be harvested and used for inoculating various cell...
10.3K
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

7.3K
We have engineered the capsid protein of hepatitis E virus as a theranostic nanoparticle (HEVNP). HEVNP self-assembles into a stable icosahedral cage in mucosal delivery. Here, we describe the modification of HEVNPs for tumor targeting by mutating surface-exposed residues to cysteines, which conjugate synthetic ligands that specifically bind tumor...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FADD is recruited to activated STING oligomers to initiate caspase-mediated NF-κB activation in Drosophila melanogaster.

The EMBO journal·2026
Same author

Integrative screening identifies functional variants and VNTRs underlying GWAS signals at the 5p15.33 multi-cancer susceptibility locus.

medRxiv : the preprint server for health sciences·2026
Same author

Prioritizing context-specific genetic risk mechanisms in 11 solid cancers.

medRxiv : the preprint server for health sciences·2025
Same author

Author Correction: Genetic regulation of TERT splicing affects cancer risk by altering cellular longevity and replicative potential.

Nature communications·2025
Same author

A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival.

Leukemia·2025
Same author

Genetic regulation of TERT splicing affects cancer risk by altering cellular longevity and replicative potential.

Nature communications·2025
Same journal

Restraint of melanoma progression by cells in the local skin environment.

eLife·2026
Same journal

Brawn before bite in endemic Asian eutherian mammals after the end-Cretaceous extinction.

eLife·2026
Same journal

Experimental evolution to thermal stress indicates climate resilience in a cosmopolitan arthropod.

eLife·2026
Same journal

Correlates of protection against African swine fever virus identified by a systems immunology approach.

eLife·2026
Same journal

Retrosplenial cortex enables context-dependent goal-directed sensorimotor transformation.

eLife·2026
Same journal

Direct contact between iPSC-derived macrophages and hepatocytes drives reciprocal acquisition of Kupffer cell identity and hepatocyte maturation.

eLife·2026
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

What makes the hepatitis C virus evolve?

Thomas R O'Brien1, Rune Hartmann2, Ludmila Prokunina-Olsson3

  • 1Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, United States.

Elife
|September 4, 2019
PubMed
Summary
This summary is machine-generated.

Genetic variations in the IFNL4 gene influence hepatitis C virus (HCV) outcomes. These IFNL4 gene polymorphisms affect protein presence and form, impacting HCV infection dynamics.

Keywords:
Hepatitis Cgeneticsgenomicshost-pathogen interactionshumaninfectious diseaseinnate immunityinterferon-lambda 4microbiologyvirus

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Related Experiment Videos

Last Updated: Jan 20, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Area of Science:

  • Genetics
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) infection is a global health concern.
  • Genetic factors play a role in HCV infection outcomes.
  • The Interferon Lambda 4 (IFNL4) gene is implicated in viral infections.

Purpose of the Study:

  • To investigate the association between IFNL4 gene polymorphisms and HCV.
  • To understand how IFNL4 protein variations affect HCV infection.

Main Methods:

  • Genotyping of IFNL4 gene polymorphisms.
  • Analysis of IFNL4 protein expression and structure.
  • Correlation studies with HCV viral load and clinical outcomes.

Main Results:

  • Specific IFNL4 gene polymorphisms are significantly associated with altered HCV infection.
  • These polymorphisms affect the presence and form of the IFNL4 protein.
  • Changes in IFNL4 protein correlate with variations in hepatitis C virus characteristics.

Conclusions:

  • IFNL4 gene variations are key determinants of hepatitis C virus infection.
  • Targeting IFNL4 pathways may offer new therapeutic strategies for HCV.